Wednesday, August 29, 2018
Investigator(s): David I Meyer, PhD
New research building render

LA BioMed announced that it has closed on the sale of its $49,835,000 Series 2018 Tax-Exempt Revenue Bonds issued by the California Health Facilities Financing Authority (CHFFA).  The proceeds of the revenue bond sale, which was led by Wells Fargo Securities, will be used to finance various capital improvements on the LA BioMed campus, including constru

Thursday, August 9, 2018
Investigator(s): Ashraf Ibrahim, PhD

Acinetobacter bacteriaA groundbreaking study by LA BioMed researchers shows promising results for a potential vaccine for deadly drug-resistant bacteria also known as superbugs.   

Thursday, August 2, 2018

LA BioMed announced the launch of two new male contraceptive studies. The preliminary study of the pill showed that the oral contraceptive appears to be safe and effective when taken daily. Current methods of male contraception include vasectomy, condoms, withdrawal, and fertility awareness.